(Q38166844)

30 August 2017

title

Rho kinase inhibitors: a patent review (2012 - 2013). (English)

1 reference

30 August 2017

Yangbo Feng

1

1 reference

30 August 2017

Philip V LoGrasso

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

27 November 2013

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

published in

1 reference

30 August 2017

volume

24

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

295-307

1 reference

Rho kinase: an important mediator of atherosclerosis and vascular disease

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho kinase, a promising drug target for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho kinase (ROCK) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The neuroprotective potential of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in response to hypoxia in isolated bovine retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho kinase inhibitors: potential treatments for diabetes and diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Regulation of Rho/ROCK signaling in airway smooth muscle by membrane potential and [Ca2+]i

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Y-27632 potentiates relaxant effects of beta 2-adrenoceptor agonists in bovine tracheal smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Emerging targets for novel therapy of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho kinase inhibitors: a novel therapeutical intervention in asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Differential effects of two ROCK inhibitors, Fasudil and Y-27632, on optic nerve regeneration in adult cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rhos and Rho kinases in the rat prostate: their possible functional roles and distributions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Correlation between Rho-kinase pathway gene expressions and development and progression of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Aberrant ROCK activation promotes the development of type I diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Pharmacological effects of latanoprost, prostaglandin E2, and F2alpha on isolated rabbit ciliary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Antedrugs: an approach to safer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Novel vitamin D3 antipsoriatic antedrugs: 16-En-22-oxa-1alpha,25-(OH)2D3 analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Design and synthesis of Rho kinase inhibitors (II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Design and synthesis of rho kinase inhibitors (III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Design and synthesis of Rho kinase inhibitors (I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Detection of myosin light chain phosphorylation--a cell-based assay for screening Rho-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Fragment-Based and Structure-Guided Discovery and Optimization of Rho Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Chroman-3-amides as potent Rho kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Amino acid derived quinazolines as Rock/PKA inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Tetrahydroisoquinoline Derivatives As Highly Selective and Potent Rho Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Benzimidazole- and benzoxazole-based inhibitors of Rho kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The development of benzimidazoles as selective rho kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Discovery of Potent and Selective Urea-Based ROCK Inhibitors and Their Effects on Intraocular Pressure in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Ceramide influences neurite outgrowth and neuroblastoma cell apoptosis regulated by novel protein kinase C isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Novel therapies for glaucoma: a patent review 2007 - 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

Un vaccin contre le glaucome, mythe ou réalité ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.863279

10.1517/13543776.2014.863279

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference